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In 1998, the Breast Cancer Prevention Trial (BCPT)
demonstrated that tamoxifen reduced the risk of invasive
breast cancer by 49% among women with no previous
history of the disease. The United States (U.S.) Food and
Drug Administration (FDA) approved tamoxifen for
breast cancer chemoprevention for women aged 35 years
or older with a 5-year breast cancer risk of at least 1.67%,
as deﬁned by the ‘‘Gail’’ Breast Cancer Risk Assessment
Model [1]. Such women are eligible in the U.S. to take
tamoxifen for chemoprevention. Freedman and collea-
gues [2] estimated that over 10 million women in the U.S.
between the ages of 35 and 79 were eligible to take
tamoxifen for breast cancer chemoprevention in 2000.
Unfortunately, tamoxifen use has been associated
with adverse outcomes, including excesses of en-
dometrial cancer, pulmonary embolism, stroke, deep
vein thrombosis, and cataracts, and not all eligible wo-
men have a positive beneﬁt/risk ratio. Using a beneﬁt/
risk index for tamoxifen chemoprevention [3], Freedman
and colleagues [2] estimated that 2.4 million U.S. would
have a net beneﬁt from taking the drug.
To obtain a nationally representative estimate of the
numbers of women taking tamoxifen for breast cancer
chemoprevention, we analysed data from the year 2000
National Health Interview Survey (NHIS) Cancer
Control Module [4–6]. Only 13 of 6569 (0.2%, 95%
Conﬁdence Interval (CI) 0.1–0.3%) white women with-
out a previous history of breast cancer, age 40 to 79
years or older reported they were currently taking ta-
moxifen. We estimated that among 42 197 968 white
women age 40–79 years in the U.S., only 70 681 (95% CI
36 284–123 984) were taking tamoxifen for chemopre-
vention. Samples were too small to give reliable esti-
mates for black and Hispanic women. Since women
were not asked about the reason for taking tamoxifen,
our estimates may exceed the actual numbers of women
taking tamoxifen for chemoprevention, because some
women who reported taking tamoxifen may have failed
to report a previous diagnosis of breast cancer.
Thus, in the year 2000, two years after the FDA’s
approval of tamoxifen for chemoprevention, few white
women were using the drug for chemoprevention com-
pared with the large numbers eligible and even com-
pared with the more modest numbers estimated to have
a positive beneﬁt/risk index. Women in the U.S. may be
unaware of the availability of a drug to prevent breast
cancer. Women may also be unaware of the risks and
beneﬁts. In a community sample of women aged 40–55
years, 23% were interested in taking a drug to prevent
breast cancer without speciﬁc information on risks and
beneﬁts, even though only 8% of these women were at
high risk [7]. Some physicians may be unclear about
when to recommend chemoprevention, may be unfa-
miliar with available beneﬁt/risk analyses, and may not
want to carry out the long-term follow-up necessary for
serious adverse events from tamoxifen.
In 2002, the U.S. Preventive Services Task Force
recommended that clinicians routinely discuss chemo-
prevention with women at high risk of breast cancer
and low risk of adverse eﬀects. A woman’s decision to
take tamoxifen to prevent breast cancer is complex and
involves how she weighs her disease risks and beneﬁts,
as well as her comorbidities, personal values, prefer-
ences, lifestyle, and speciﬁc medical situation. The data
presented here indicate a need for educating healthcare
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professionals and for providing tools to help assess the
risks and beneﬁts of tamoxifen for chemoprevention in
their patients.
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